220 related articles for article (PubMed ID: 37650685)
1. MicroRNA regulation of the serine synthesis pathway in endocrine-resistant breast cancer cells.
Petri BJ; Piell KM; Wilt AE; Howser AD; Winkler L; Whitworth MR; Valdes BL; Lehman NL; Clem BF; Klinge CM
Endocr Relat Cancer; 2023 Nov; 30(11):. PubMed ID: 37650685
[TBL] [Abstract][Full Text] [Related]
2. HNRNPA2B1 regulates tamoxifen- and fulvestrant-sensitivity and hallmarks of endocrine resistance in breast cancer cells.
Petri BJ; Piell KM; South Whitt GC; Wilt AE; Poulton CC; Lehman NL; Clem BF; Nystoriak MA; Wysoczynski M; Klinge CM
Cancer Lett; 2021 Oct; 518():152-168. PubMed ID: 34273466
[TBL] [Abstract][Full Text] [Related]
3. Serine synthesis influences tamoxifen response in ER+ human breast carcinoma.
Metcalf S; Petri BJ; Kruer T; Green B; Dougherty S; Wittliff JL; Klinge CM; Clem BF
Endocr Relat Cancer; 2021 Jan; 28(1):27-37. PubMed ID: 33112838
[TBL] [Abstract][Full Text] [Related]
4. HNRNPA2/B1 is upregulated in endocrine-resistant LCC9 breast cancer cells and alters the miRNA transcriptome when overexpressed in MCF-7 cells.
Klinge CM; Piell KM; Tooley CS; Rouchka EC
Sci Rep; 2019 Jul; 9(1):9430. PubMed ID: 31263129
[TBL] [Abstract][Full Text] [Related]
5. Tamoxifen differentially regulates miR-29b-1 and miR-29a expression depending on endocrine-sensitivity in breast cancer cells.
Muluhngwi P; Krishna A; Vittitow SL; Napier JT; Richardson KM; Ellis M; Mott JL; Klinge CM
Cancer Lett; 2017 Mar; 388():230-238. PubMed ID: 27986463
[TBL] [Abstract][Full Text] [Related]
6. miR-449a Suppresses Tamoxifen Resistance in Human Breast Cancer Cells by Targeting ADAM22.
Li J; Lu M; Jin J; Lu X; Xu T; Jin S
Cell Physiol Biochem; 2018; 50(1):136-149. PubMed ID: 30278449
[TBL] [Abstract][Full Text] [Related]
7. Reduced expression of miR-200 family members contributes to antiestrogen resistance in LY2 human breast cancer cells.
Manavalan TT; Teng Y; Litchfield LM; Muluhngwi P; Al-Rayyan N; Klinge CM
PLoS One; 2013; 8(4):e62334. PubMed ID: 23626803
[TBL] [Abstract][Full Text] [Related]
8. [Urothelial carcinoma-associated 1 enhances tamoxifen resistance in breast cancer cells through competitively inhibiting miR-18a].
Li XN; Liu AH; Tang X; Ren Y
Beijing Da Xue Xue Bao Yi Xue Ban; 2017 Apr; 49(2):295-302. PubMed ID: 28416841
[TBL] [Abstract][Full Text] [Related]
9. The miR-29 transcriptome in endocrine-sensitive and resistant breast cancer cells.
Muluhngwi P; Alizadeh-Rad N; Vittitow SL; Kalbfleisch TS; Klinge CM
Sci Rep; 2017 Jul; 7(1):5205. PubMed ID: 28701793
[TBL] [Abstract][Full Text] [Related]
10. CUL4B renders breast cancer cells tamoxifen-resistant via miR-32-5p/ER-α36 axis.
Wang Y; Pan X; Li Y; Wang R; Yang Y; Jiang B; Sun G; Shao C; Wang M; Gong Y
J Pathol; 2021 Jun; 254(2):185-198. PubMed ID: 33638154
[TBL] [Abstract][Full Text] [Related]
11. WBP2 modulates G1/S transition in ER+ breast cancer cells and is a direct target of miR-206.
Ren YQ; Wang HJ; Zhang YQ; Liu YB
Cancer Chemother Pharmacol; 2017 May; 79(5):1003-1011. PubMed ID: 28391353
[TBL] [Abstract][Full Text] [Related]
12. MiR-148a and miR-152 reduce tamoxifen resistance in ER+ breast cancer via downregulating ALCAM.
Chen MJ; Cheng YM; Chen CC; Chen YC; Shen CJ
Biochem Biophys Res Commun; 2017 Feb; 483(2):840-846. PubMed ID: 28063929
[TBL] [Abstract][Full Text] [Related]
13. A miR-26a/E2F7 feedback loop contributes to tamoxifen resistance in ER-positive breast cancer.
Liu J; Li X; Wang M; Xiao G; Yang G; Wang H; Li Y; Sun X; Qin S; Du N; Ren H; Pang Y
Int J Oncol; 2018 Oct; 53(4):1601-1612. PubMed ID: 30066905
[TBL] [Abstract][Full Text] [Related]
14. MiR-214 increases the sensitivity of breast cancer cells to tamoxifen and fulvestrant through inhibition of autophagy.
Yu X; Luo A; Liu Y; Wang S; Li Y; Shi W; Liu Z; Qu X
Mol Cancer; 2015 Dec; 14():208. PubMed ID: 26666173
[TBL] [Abstract][Full Text] [Related]
15. The ERα-miR-575-p27 feedback loop regulates tamoxifen sensitivity in ER-positive Breast Cancer.
Liu SS; Li Y; Zhang H; Zhang D; Zhang XB; Wang X; Yu Y
Theranostics; 2020; 10(23):10729-10742. PubMed ID: 32929377
[No Abstract] [Full Text] [Related]
16. Estrogen receptor alpha 46 is reduced in tamoxifen resistant breast cancer cells and re-expression inhibits cell proliferation and estrogen receptor alpha 66-regulated target gene transcription.
Klinge CM; Riggs KA; Wickramasinghe NS; Emberts CG; McConda DB; Barry PN; Magnusen JE
Mol Cell Endocrinol; 2010 Jul; 323(2):268-76. PubMed ID: 20302909
[TBL] [Abstract][Full Text] [Related]
17. miR-378a-3p modulates tamoxifen sensitivity in breast cancer MCF-7 cells through targeting GOLT1A.
Ikeda K; Horie-Inoue K; Ueno T; Suzuki T; Sato W; Shigekawa T; Osaki A; Saeki T; Berezikov E; Mano H; Inoue S
Sci Rep; 2015 Aug; 5():13170. PubMed ID: 26255816
[TBL] [Abstract][Full Text] [Related]
18. Downregulation of miR-342 is associated with tamoxifen resistant breast tumors.
Cittelly DM; Das PM; Spoelstra NS; Edgerton SM; Richer JK; Thor AD; Jones FE
Mol Cancer; 2010 Dec; 9():317. PubMed ID: 21172025
[TBL] [Abstract][Full Text] [Related]
19. Integrative analysis of miRNA and gene expression reveals regulatory networks in tamoxifen-resistant breast cancer.
Joshi T; Elias D; Stenvang J; Alves CL; Teng F; Lyng MB; Lykkesfeldt AE; Brünner N; Wang J; Gupta R; Workman CT; Ditzel HJ
Oncotarget; 2016 Aug; 7(35):57239-57253. PubMed ID: 27528030
[TBL] [Abstract][Full Text] [Related]
20. MicroRNA-125b upregulation confers aromatase inhibitor resistance and is a novel marker of poor prognosis in breast cancer.
Vilquin P; Donini CF; Villedieu M; Grisard E; Corbo L; Bachelot T; Vendrell JA; Cohen PA
Breast Cancer Res; 2015 Jan; 17(1):13. PubMed ID: 25633049
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]